PIERREL S.P.A TO PRESENT AT THE LIFE SCIENCES ISRAEL 2013 IN TEL AVIV

PIERREL S.P.A TO PRESENT AT THE LIFE SCIENCES ISRAEL 2013 IN TEL AVIV

Zurich, Switzerland, 9 October 2013 – Pierrel S.p.A, a full service global provider for life science, biopharma and pharmaceutical industries, today announced that Ms Maxime Stevens, their Group Chief Executive Officer of Pierrel Research, has been invited to present at the 2nd Annual International Partnering of the Israeli BioMedTech Industry, Life Sciences Israel 2013, taking place on the 16th and 17th October 2013, in Tel Aviv, Israel.

Ms. Stevens will be discussing the latest growth, innovations and core values that the Pierrel SpA Group deliver through their four divisions; Discovery, Clinical Research, CMO and Pharmaceuticals. Particular focus will be upon the most recent acquisition within the group.

  •  The emergence of our new Group THERAMetrics Holdings AG
  • The launch of Search & Match Intelligence (SMI), a unique and innovative tool with the huge potential to influence and alter drug discovery and delivery of tomorrow
  • The Groups International and regional structure and focus on delivery of a complete and comprehensive provision of services that encompasses discovery, delivery, manufacturing and provision of pharmaceuticals.

Life Sciences Israel TM 2013 is an initiative from Circle of Life (Israel's leading members club for the BioMedTech industry) that presents an international partnering platform that is focused mainly on one-to-one meetings and deal making opportunities of decision makers and investors from Israel and abroad.

Organized in response to the growing demand for an efficient healthcare partnering forum where companies can actually meet to discuss defined business, Life Sciences Israel TM 2013 provides medical companies the opportunity to present and partner with an audience of local and global business executives.

Press Release

The Pierrel Group, through the combination of advanced bio-modelling and science, successfully competes in the current market environment by offering consultancy services for clinical and regulatory development programmes, as well as operational services to effectively conduct global Phase I - IV clinical trials, late phase, and Non-Interventional Studies ("NIS").

Our key competitive strengths include our drug discovery bio-mathematical platform (Search & Match Intelligence), which enables companies to repurpose or redirect existing compounds to other indications, and facilitates identifying emerging paths though the patho-physiological indications and symptoms of diseases.

Pierrel Research Clinical Research Group has more than 20 years' experience as a full-service Contract Research Organization, delivering drug development services to the pharmaceutical, biotechnology, and medical device industries as well as offering full IMP services. With over 265 clinical staff strategically located in more than 20 countries worldwide, enabling a high level of local expertise to be applied to global clinical trials of all sizes. Our international and highly skilled multidisciplinary teams work to consistently offer high quality, flexible and cost effective services and solutions across the full spectrum of clinical research and regulatory requirements.

Our CMO and Pharma divisions have more than 50 years' experience in both pharmaceutical and life science services. Local anaesthetics have been manufactured at Pierrel since the early 1960's; our production site has been approved by EMA for aseptic production of dental anaesthetics since 1989, and FDA approved since October 2009 for the production of "Sterile Filled Small Volumes Parenteral Drugs"

From clinical concept to commercial delivery; our supply chain consistently delivers, with our ethical values and focus always on the patient.

Media Contact:
Maxime Stevens
Tel: +39 02 24134 206
[email protected]

Suggested Articles

Biogen stunned the biotech world Tuesday when it said it would file aducanumab for approval. Now that the dust has settled, what are analysts saying?

Biocytogen uses chromosome engineering for the in situ replacement of mouse antibody genes with the human counterparts.

Eli Lilly is canning the lead program for the crown jewel of its $1.6 billion Armo buyout after the drug put up a poor showing in pancreatic cancer.